Akari Therapeutics Plc · Purchase · Pre-Funded Warrants to purchase ADRs

What does this filing report?

An SEC Form 4 filing for Akari Therapeutics Plc records a purchase involving Pre-Funded Warrants to purchase ADRs on December 16, 2025. The reported quantity was 24,745. The filing date is December 18, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Derivative terms

Underlying security

American Depositary Shares representing Ordinary Shares

Underlying quantity

24,745

Conversion / exercise price

0

Exercise date

Not reported

Expiration date

Not reported

Filing footnotes & remarks

F1

Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer.

F2

On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 24,745 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 24,745 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.

F3

The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the Private Placement Unregistered Warrants remaining exercisable until fully exercised.

F4

The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041.

F5

Conversion Exercise Price of Security is $0.00001

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.